Shahram Hejazi

Overview

BioAdvance is an evergreen fund established to address the critical needs of emerging human life science-focused companies. Committed to fueling innovation, BioAdvance supports companies dedicated to developing technologies that can meaningfully impact human health. This support has empowered innovators to advance groundbreaking health technologies and expand access to subsequent funding through venture capital, grants, collaborations, and mergers and acquisitions. Our investment philosophy is centered on strategic, impactful capital that drives companies to critical milestones. Our initial investment size typically ranges from $500,000 to $1,500,000, and we have the ability to commit up to $5 million over the lifecycle of a company. While we are open to participating in funding rounds of any size, our focus is on supporting early-stage ventures on the path to significant value creation. We would consider leading rounds between $500,000 and $5 million, bringing expertise and capital to accelerate product development, market validation, and growth initiatives. Our goal is to position companies for success in future fundraising rounds, enabling them to capture their market potential and scale effectively. BioAdvance is a $80-million early-stage life sciences fund with a focus in the mid-Atlantic region, investing in companies that have the potential to improve human health. Since making its first investments in 2003, BioAdvance has committed more than $55 million in funding to approximately 100 organizations developing more than 160 products in the diagnostics, therapeutic, medtech, research tools, and digital health sectors. BioAdvance portfolio companies have leveraged $3.8 billion in subsequent capital, including proceeds from acquisitions. Eleven products have received FDA approval.

Investment Focus

• Early-stage life sciences companies with potential to improve human health

Portfolio Companies